Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate

Journal of Pharmaceutical Sciences

Volumn 99, Issue 8, 2010, Pages 3415-3429

  Xu, Zhen ^a   Mansour, Heidi M ^a,d   Mulder, Tako ^b   Mclean, Richard ^c   Langridge, John ^b   Hickey, Anthony J ^a  

^a University of North Carolina   (United States)

^b DMV Fonterra Excipients   (Germany)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d University of Kentucky   (United States)

Author keywords

Aerosolization performance; Aerosols; Dry powder inhaler; Emitted dose; Fine particle fraction; Physical characterization; Powder aerosol deaggregation equation; Pulmonary drug delivery; Shear stress; Standardized entrainment tubes

Indexed keywords

FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; LACTOSE; AEROSOL; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG CARRIER; FLUTICASONE; POWDER;

AEROSOL; ARTICLE; DRUG STRUCTURE; DRY POWDER; MORPHOLOGY; PARTICLE SIZE; SHEAR STRESS; THERMAL ANALYSIS; X RAY POWDER DIFFRACTION; ALGORITHM; CHEMISTRY; DEVICES; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; INHALATIONAL DRUG ADMINISTRATION; LASER; POWDER; PROCEDURES; SCANNING ELECTRON MICROSCOPY; X RAY DIFFRACTION;

ADMINISTRATION, INHALATION; AEROSOLS; ALGORITHMS; ANDROSTADIENES; BRONCHODILATOR AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG CARRIERS; DRUG COMPOUNDING; IPRATROPIUM; LACTOSE; LASERS; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDERS; X-RAY DIFFRACTION;

EID: 77955105106     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22100     Document Type: Article

References (34)

1. Crowder TM, Hickey AJ, Louey MD, Orr N. 2003. A guide to pharmaceutical particulate science. In: Crowder TM, editor. A guide to pharmaceutical particulate science. Boca Raton, FL: Interpharm Press/CRC PP 19-21.
2. Chew NY, Bagster DF, Chan HK. 2000. Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders. Int J Pharm 206:75-83.
3. Steckel H, Muller BW. 1997. In vitro evaluation of dry powder inhalers II: Influence of carrier particle size and concentration on in vitro deposition. Int J Pharm 154:31-37.
4. Chew NY, Chan HK. 2002. Effect of powder polydispersity on aerosol generation. J Pharm Sci 5:162-168.
5. Chan HK. 2008. What is the role of particle morphology in pharmaceutical powder aerosols? Expert Opin Drug Deliv 5:909-914.
6. Chew NY, Tang P, Chan HK, Raper JA. 2005. How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm Res 22:148-152.
7. Young PM, Chan HK, Chiou H, Edge S, Tee TH, Traini D. 2007. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance. J Pharm Sci 96:1331-1341. (Pubitemid 46804584)
8. Jones MD, Price R. 2006. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm Res 23:1665-1674.
9. Young PM, Edge S, Traini D, Jones MD, Price R, El-Sabawi D, Urry C, Smith C. 2005. The influence of dose on the performance of dry powder inhalation systems. Int J Pharm 296:26-33.
10. Lechuga-Ballesteros D, Charan C, Stults CL, Stevenson CL, Miller DP, Vehring R, Tep V, Kuo MC. 2008. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci 97:287-302.
11. Perkins M, Ebbens SJ, Hayes S, Roberts CJ, Madden CE, Luk SY, Patel N. 2007. Elastic modulus measurements from individual lactose particles using atomic force microscopy. Int J Pharm 332:168-175. (Pubitemid 46251367)
12. Mohammed A, Reddy RN, Mazumder MK. 2008. Simultaneous characterization of aerodynamic size and electrostatic charge distributions of inhaled dry powder inhaler aerosols. Curr Resp Med Rev 4:2-5.
13. Young PM, Price R. 2004. The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate. Eur J Pharm Sci 22:235-240.
14. Zeng XM, MacRitchie HB, Marriott C, Martin GP. 2007. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers. Int J Pharm 333:45-55.
15. Islam N, Gladki E. 2008. Dry powder inhalers (DPIs) - A review of device reliability and innovation. Int J Pharm 360:1-11.
16. Dunbar CA, Hickey AJ, Holzner P. 1998. Dispersion and characterization of pharmaceutical dry powder aerosols. Kona 16:7-45.
17. Louey MD, VanOort M, Hickey AJ. 2006. Standardized entrainment tubes for the evaluation of pharmaceutical dry powder dispersion. J Aerosol Sci 37:1520-1533.
18. Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ. 2009. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. albuterol sulfate and disodium cromoglycate. J Pharm Sci. submitted.
19. Mansour HM, Xu Z, Hickey AJ. 2010. Dry powder aerosols generated by standardized entrainment tubes from alternative sugar blends: 3. Trehalose dehydrate and D-mannitol carriers. J Pharm Sci. 99:xxxx-xxxx.
20. Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ. 2009. Heterogenous particle deaggregation and its implications for therapeutic aerosol performance. J Pharm Sci submitted.
21. van Zyl JM, Derendinger B, Seifart HI, Van der Bijl P. 2008. Comparative diffusion of drugs through bronchial tissue. Int J Pharm 357:32-36.
22. Taylor MK. 2001. Particle engineering to achieve optimal morphology and physicochemical characteristics for aerosol delivery of ipratropium bromide. Ph.D Thesis. Chapel Hill: University of North Carolina. pp. 72-100.
23. Kerstjens H, Postma D, ten Hacken N. 2005. Chronic obstructive pulmonary disease. Clin Evid. 13:1923-1947.
24. Baptist AP, Reddy RC. 2009. Inhaled corticosteroids for asthma: Are they all the same? J Clin Pharm Ther 34:1-12.
25. Crim C, Pierre LN, Daley-Yates PT. 2001. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 23:1339-1354. (Pubitemid 32912787)
26. Newton R. 2000. Molecular mechanisms of glucocorticoid action: What is important? Thorax 55:603-613.
27. Kim YH. 2008. Supercritical fluid-micronized ipratropium bromide for pulmonary drug delivery. Powder Tech 182:25-32.
28. Louey MD, Van Oort M, Hickey AJ. 2004. Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactose-blend formulations. Pharm Res 21:1207-1213. (Pubitemid 38954205)
29. Corrigan DO, Corrigan OI, Healy AM. 2006. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. Int J Pharm 322:22-30.
30. Westmeier R, Steckel H. 2008. Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment. J Pharm Sci 97:2299-2310.
31. Brittain HG, Florey K. 2003. Profiles of drug substances, excipients and related methodology. New York, NY: Elsevier, Inc. pp 59-83.
32. Cooper Simon Murray Development GWR. 1998. A novel polymorphic crystalline form of fluticasone propionate, a method for its production and pharmaceutical compositions thereof. In organization Wip, editor International Bureau, C07J 31/00, A61K 31/56 ed., UK. pp 83.
33. Beilmann B, Kubiak R, Grab P, Hausler H, Langguth P. 2007. Effect of interactive ternary mixtures on dispersion characteristics of ipratropium bromide in dry powder inhaler formulations. AAPS PharmSciTech 8: Article 31.
34. Jones MD, Hooton JC, Dawson ML, Ferrie AR, Price R. 2008. An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces. Pharm Res 25:337-348.